TB-500 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. Total weekly dose averages ~5 mg, consistent with research protocols.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; do not freeze reconstituted solution as freezing can denature

peptides.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Use reconstituted vials within 28 days when stored with bacteriostatic water preservative.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (TB-500, 10 mg each):

• 8 weeks: ~4 vials. 12 weeks: ~7 vials. 16 weeks: ~10 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (4 vials): 2 bottles. 12 weeks (7 vials): 3 bottles. 16 weeks (10 vials): 3 bottles.

Alcohol Swabs:

• Per week: 14 swabs (2/day).
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy.
• Inject slowly; wait a few seconds before withdrawing the needle to prevent backflow.
• Document daily dose, injection site, and any observations to maintain consistency.
• Regulatory Note: TB-500 is banned by WADA for athletic use and is not FDA-approved for human

administration.

How This Works

TB-500 represents the N-terminal active fragment of thymosin beta-4, specifically the heptapeptide sequence Ac-LKKTETQ. This region is responsible for the actin-binding and cell-migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB-500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation. Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments. Recent metabolic studies suggest TB-500 may act as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity.

Benefits & Side Effects

Observations from preclinical and veterinary literature.

• Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell

migration.

• May reduce inflammation and fibrosis indirectly via thymosin pathways observed in animal models.
• Generally well tolerated in veterinary studies; occasional mild injection-site reactions (redness,

tenderness) reported.

• Human safety data is limited; no large-scale clinical trials have been completed for TB-500 specifically.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain adequate protein intake to support tissue repair and regeneration processes.
• Combine with appropriate physical activity; avoid overtraining during injury recovery phases.
• Prioritize sleep (7 to 9 hours) to maximize natural recovery and repair mechanisms.
• Manage stress levels through evidence-based practices to support overall healing.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Biological activities of thymosin b4 defined by active peptide sequences (FASEB Journal).
2. Thymosin beta4 accelerates wound healing (Journal of Investigative Dermatology).
3. Active site mapping of thymosin b4 fragments for angiogenesis and cell migration (FASEB Journal).
4. Quantification of TB-500 metabolites and wound healing activity screening (Journal of Chromatography B).